🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Pauline Funchain

Palo Alto University

ORCID: 0000-0002-7568-8626

Also affiliated with Stanford Medicine, Stanford University

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 5%percentile
0.386Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma

PLoS ONE(2023)10.1371/journal.pone.0269324
Top 47%
0.386DataRank
Top 47%10 citations

Keimya Sadeghi, Sharon N. Edmiston, Jessica M. Kenney, Cecilia Lezcano, James S. Wilmott +47 more

Papers

Driven by 15 papers — median percentile 26. Top paper: “Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134”.

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

Journal of Clinical Oncology(2022)10.1200/jco.22.01763
N/A
5.4DataRank · unranked
446 citations

Sandra J. Lee, Bartosz Chmielowski, Ahmad A. Tarhini, Gary I. Cohen, Thach‐Giao Truong +31 more

Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9501
N/A
1.3DataRank · unranked
18 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Teresa M. Petrella +15 more

Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study

Pigment Cell & Melanoma Research(2022)10.1111/pcmr.13058
N/A
0.672DataRank · unranked
21 citations

Ronglai Shen, Arshi Arora, Irene Orlow, Klaus J. Busam, Cecilia Lezcano +40 more

InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma

PLoS ONE(2023)10.1371/journal.pone.0269324
Top 47%
0.386DataRank
Top 47%10 citations

Keimya Sadeghi, Sharon N. Edmiston, Jessica M. Kenney, Cecilia Lezcano, James S. Wilmott +47 more

DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance

JCO Precision Oncology(2024)10.1200/po-24-00375
N/A
0.327DataRank · unranked
6 citations

Sharon N. Edmiston, Amanda M. Vondras, Allison Reiner, David L. Corcoran, Ronglai Shen +70 more

Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study

UNC Libraries(2023)10.17615/43x8-9d17
N/A
0.165DataRank · unranked
2 citations

M. Berwick, InterMEL, Li Luo, Judy R. Rees, Sheri L. Holmen +40 more

Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

(2023)10.1158/2159-8290.c.6549583.v1
N/A
0DataRank · unranked
0 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma

UNC Libraries(2023)10.17615/btmj-c685
Top 100%
0DataRank
Top 100%0 citations

R.A. Scolyer, C.B. Begg, Iman Osman, C Timothy Thompson, Elise K. Brunsgaard +48 more

Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2381
N/A
0DataRank · unranked
145 citations

Manu Pandey, Kristopher Attwood, Wenyan Ji, Agnieszka K. Witkiewicz, Erik S. Knudsen +14 more

Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2025-011865
N/A
0DataRank · unranked
5 citations

Yee-Ming Melody Cheung, Cherie Chiang, Emily J. Gallagher, Ole‐Petter R. Hamnvik, Jennifer S. Mammen +32 more

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2019-000331
N/A
0DataRank · unranked
125 citations

Kristina Navrazhina, Fei Ding, Roma Bhatia, Katy K. Tsai, Kelly Abbate +23 more

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Cancer Discovery(2021)10.1158/2159-8290.cd-21-1141
N/A
0DataRank · unranked
102 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

MC1R signaling through the cAMP-CREB/ATF-1 and ERK-NFκB pathways accelerates G1/S transition promoting breast cancer progression

npj Precision Oncology(2023)10.1038/s41698-023-00437-1
N/A
0DataRank · unranked
17 citations

Kiara Thomas, Todd Romigh, Andrew Fong, Lin Li, Shira Ronen +5 more

Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer

Journal of Cancer(2023)10.7150/jca.84261
N/A
0DataRank · unranked
9 citations

Malek Shatila, Antony Mathew, Antonio Pizuorno Machado, Austin R. Thomas, Hao Chi Zhang +9 more

Data from Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

(2023)10.1158/1078-0432.c.6530279
N/A
0DataRank · unranked
0 citations

Manu Pandey, Kristopher Attwood, Wenyan Ji, Agnieszka K. Witkiewicz, Erik S. Knudsen +14 more